180 related articles for article (PubMed ID: 30014821)
1. Operational Performance of the
Richards FO; Katabarwa M; Bekele F; Tadesse Z; Mohammed A; Sauerbrey M; Dominguez-Vazquez A; Rodriguez-Perez MA; Fernández-Santos NA; Rizzo N; Schuler Martínez HR; Lovato Silva R; Morales Monroy Z; Habomugisha P; Oguttu DW; Zarroug IMA; Aziz NA; Unnasch TR
Am J Trop Med Hyg; 2018 Sep; 99(3):749-752. PubMed ID: 30014821
[TBL] [Abstract][Full Text] [Related]
2. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
[TBL] [Abstract][Full Text] [Related]
3. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
[TBL] [Abstract][Full Text] [Related]
4. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580
[TBL] [Abstract][Full Text] [Related]
5. Assessment and monitoring of onchocerciasis in Latin America.
Rodríguez-Pérez MA; Unnasch TR; Real-Najarro O
Adv Parasitol; 2011; 77():175-226. PubMed ID: 22137585
[TBL] [Abstract][Full Text] [Related]
6. The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria.
Richards FO; Eigege A; Umaru J; Kahansim B; Adelamo S; Kadimbo J; Danboyi J; Mafuyai H; Saka Y; Noland GS; Anyaike C; Igbe M; Rakers L; Griswold E; Unnasch TR; Nwoke BEB; Miri E
Am J Trop Med Hyg; 2020 Mar; 102(3):582-592. PubMed ID: 32043442
[TBL] [Abstract][Full Text] [Related]
7. Analysis of age-dependent trends in Ov16 IgG4 seroprevalence to onchocerciasis.
Golden A; Faulx D; Kalnoky M; Stevens E; Yokobe L; Peck R; Karabou P; Banla M; Rao R; Adade K; Gantin RG; Komlan K; Soboslay PT; de Los Santos T; Domingo GJ
Parasit Vectors; 2016 Jun; 9(1):338. PubMed ID: 27296630
[TBL] [Abstract][Full Text] [Related]
8. The positive influence the Onchocerciasis Elimination Program for the Americas has had on Africa programs.
Richards FO; Nwoke BEB; Zarroug I; Tukahebwa E; Negussu N; Higazi TB; Oguttu D; Tadesse Z; Miri E; Aziz N; Habomugisha P; Katabarwa M
Infect Dis Poverty; 2019 Jul; 8(1):52. PubMed ID: 31303175
[TBL] [Abstract][Full Text] [Related]
9. Relationship between skin snip and Ov16 ELISA: Two diagnostic tools for onchocerciasis in a focus in Cameroon after two decades of ivermectin-based preventive chemotherapy.
Djune-Yemeli L; Domché A; Nana-Djeunga HC; Donfo-Azafack C; Lenou-Nanga CG; Masumbe-Netongo P; Kamgno J
PLoS Negl Trop Dis; 2022 May; 16(5):e0010380. PubMed ID: 35499993
[TBL] [Abstract][Full Text] [Related]
10. The interruption of Onchocerca volvulus and Wuchereria bancrofti transmission by integrated chemotherapy in the Obongi focus, North Western Uganda.
Luroni LT; Gabriel M; Tukahebwa E; Onapa AW; Tinkitina B; Tukesiga E; Nyaraga M; Auma AM; Habomugisha P; Byamukama E; Oguttu D; Katabarwa M; Unnasch TR
PLoS One; 2017; 12(12):e0189306. PubMed ID: 29253862
[TBL] [Abstract][Full Text] [Related]
11. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes.
Dadzie Y; Amazigo UV; Boatin BA; Sékétéli A
Infect Dis Poverty; 2018 Jul; 7(1):63. PubMed ID: 29966535
[TBL] [Abstract][Full Text] [Related]
12. The Galabat-Metema cross-border onchocerciasis focus: The first coordinated interruption of onchocerciasis transmission in Africa.
Katabarwa MN; Zarroug IMA; Negussu N; Aziz NM; Tadesse Z; Elmubark WA; Shumo Z; Meribo K; Kamal H; Mohammed A; Bitew Y; Seid T; Bekele F; Yilak A; Endeshaw T; Hassen M; Tillahun A; Samuel F; Birhanu H; Asmare T; Boakye D; Feleke SM; Unnasch T; Post R; Higazi T; Griswold E; Mackenzie C; Richards F
PLoS Negl Trop Dis; 2020 Feb; 14(2):e0007830. PubMed ID: 32027648
[TBL] [Abstract][Full Text] [Related]
13. Assessing Hypoendemic Onchocerciasis in
Rakers LJ; Emukah E; Kahansim B; Nwoke BEB; Miri ES; Griswold E; Davies E; Ityonzughul C; Anyaike C; Agbi P; Richards FO
Am J Trop Med Hyg; 2020 Dec; 103(6):2328-2335. PubMed ID: 32959756
[TBL] [Abstract][Full Text] [Related]
14. Progress towards elimination of onchocerciasis transmission in Mali: A "pre-stop MDA" survey in 18 transmission zones.
Dolo H; Coulibaly ME; Sow M; Coulibaly YI; Doumbia M; Sangare M; Sanogo A; Dembele B; Guindo B; Coulibaly M; Keita M; Soumaoro L; Diarra D; Dicko B; Hamill L; Doumbia S; Sangho H; Sangare Y; Zhang Y; Tallant J; Yaro AS; Mackenzie C; Nutman TB; Boakye D
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011632. PubMed ID: 37967137
[TBL] [Abstract][Full Text] [Related]
15. Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes.
Lont YL; Coffeng LE; de Vlas SJ; Golden A; de Los Santos T; Domingo GJ; Stolk WA
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005314. PubMed ID: 28114304
[TBL] [Abstract][Full Text] [Related]
16. Interruption of Onchocerca volvulus transmission in the Abu Hamed focus, Sudan.
Higazi TB; Zarroug IM; Mohamed HA; Elmubark WA; Deran TC; Aziz N; Katabarwa M; Hassan HK; Unnasch TR; Mackenzie CD; Richards F; Hashim K
Am J Trop Med Hyg; 2013 Jul; 89(1):51-7. PubMed ID: 23690554
[TBL] [Abstract][Full Text] [Related]
17. The Onchocerciasis Elimination Program for the Americas (OEPA).
Sauerbrey M
Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
[TBL] [Abstract][Full Text] [Related]
18. Patent infections with soil-transmitted helminths and Schistosoma mansoni are not associated with increased prevalence of antibodies to the Onchocerca volvulus peptide epitopes OvMP-1 and OvMP-23.
Vlaminck J; Lagatie O; Verheyen A; Dana D; Van Dorst B; Mekonnen Z; Levecke B; Stuyver LJ
Parasit Vectors; 2019 Jan; 12(1):63. PubMed ID: 30691520
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of Ov16 Antibody Prevalence in Different Subpopulations for Elimination of African Onchocerciasis.
Coffeng LE; Stolk WA; Golden A; de Los Santos T; Domingo GJ; de Vlas SJ
Am J Epidemiol; 2019 Sep; 188(9):1723-1732. PubMed ID: 31062838
[TBL] [Abstract][Full Text] [Related]
20. Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana.
Otabil KB; Basáñez MG; Ankrah B; Opoku SA; Kyei DO; Hagan R; Ababio R; Bart-Plange EJ; Babae TN; Kudzordzi PC; Darko VA; Bamfo JG; Ameyaw J; Raji AS; Hadermann A; Schallig HDFH; Colebunders R
Trop Med Int Health; 2023 Nov; 28(11):844-854. PubMed ID: 37846505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
